Protease-activated receptor 4: From structure to function and back again

Shauna Louise French, Justin Raymond Hamilton

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Protease-activated receptors are a family of four GPCRs (PAR1-PAR4) with a number of unique attributes. Nearly two and a half decades after the discovery of the first PAR, an antagonist targeting this receptor has been approved for human use. The first-in-class PAR1 antagonist, vorapaxar, was approved for use in the USA in 2014 for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. These recent developments indicate the clinical potential of manipulating PAR function. While much work has been aimed at uncovering the function of PAR1 and, to a lesser extent, PAR2, comparatively little is known regarding the pharmacology and physiology of PAR3 and PAR4. Recent studies have begun to develop the pharmacological and genetic tools required to study PAR4 function in detail, and there is now emerging evidence for the function of PAR4 in disease settings. In this review, we detail the discovery, structure, pharmacology, physiological significance and therapeutic potential of PAR4
Original languageEnglish
Pages (from-to)2952 - 2965
Number of pages14
JournalBritish Journal of Pharmacology
Volume173
Issue number20
DOIs
Publication statusPublished - 2016

Cite this

@article{12a35173e85249dea8a47bf339aac0e3,
title = "Protease-activated receptor 4: From structure to function and back again",
abstract = "Protease-activated receptors are a family of four GPCRs (PAR1-PAR4) with a number of unique attributes. Nearly two and a half decades after the discovery of the first PAR, an antagonist targeting this receptor has been approved for human use. The first-in-class PAR1 antagonist, vorapaxar, was approved for use in the USA in 2014 for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. These recent developments indicate the clinical potential of manipulating PAR function. While much work has been aimed at uncovering the function of PAR1 and, to a lesser extent, PAR2, comparatively little is known regarding the pharmacology and physiology of PAR3 and PAR4. Recent studies have begun to develop the pharmacological and genetic tools required to study PAR4 function in detail, and there is now emerging evidence for the function of PAR4 in disease settings. In this review, we detail the discovery, structure, pharmacology, physiological significance and therapeutic potential of PAR4",
author = "French, {Shauna Louise} and Hamilton, {Justin Raymond}",
year = "2016",
doi = "10.1111/bph.13455Document",
language = "English",
volume = "173",
pages = "2952 -- 2965",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "20",

}

Protease-activated receptor 4 : From structure to function and back again. / French, Shauna Louise; Hamilton, Justin Raymond.

In: British Journal of Pharmacology, Vol. 173, No. 20, 2016, p. 2952 - 2965.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Protease-activated receptor 4

T2 - From structure to function and back again

AU - French, Shauna Louise

AU - Hamilton, Justin Raymond

PY - 2016

Y1 - 2016

N2 - Protease-activated receptors are a family of four GPCRs (PAR1-PAR4) with a number of unique attributes. Nearly two and a half decades after the discovery of the first PAR, an antagonist targeting this receptor has been approved for human use. The first-in-class PAR1 antagonist, vorapaxar, was approved for use in the USA in 2014 for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. These recent developments indicate the clinical potential of manipulating PAR function. While much work has been aimed at uncovering the function of PAR1 and, to a lesser extent, PAR2, comparatively little is known regarding the pharmacology and physiology of PAR3 and PAR4. Recent studies have begun to develop the pharmacological and genetic tools required to study PAR4 function in detail, and there is now emerging evidence for the function of PAR4 in disease settings. In this review, we detail the discovery, structure, pharmacology, physiological significance and therapeutic potential of PAR4

AB - Protease-activated receptors are a family of four GPCRs (PAR1-PAR4) with a number of unique attributes. Nearly two and a half decades after the discovery of the first PAR, an antagonist targeting this receptor has been approved for human use. The first-in-class PAR1 antagonist, vorapaxar, was approved for use in the USA in 2014 for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. These recent developments indicate the clinical potential of manipulating PAR function. While much work has been aimed at uncovering the function of PAR1 and, to a lesser extent, PAR2, comparatively little is known regarding the pharmacology and physiology of PAR3 and PAR4. Recent studies have begun to develop the pharmacological and genetic tools required to study PAR4 function in detail, and there is now emerging evidence for the function of PAR4 in disease settings. In this review, we detail the discovery, structure, pharmacology, physiological significance and therapeutic potential of PAR4

UR - http://onlinelibrary.wiley.com.ezproxy.lib.monash.edu.au/doi/10.1111/bph.13455/abstract?systemMessage=Wiley+Online+Library+will+be+unavailable+on+Satu

U2 - 10.1111/bph.13455Document

DO - 10.1111/bph.13455Document

M3 - Article

VL - 173

SP - 2952

EP - 2965

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 20

ER -